Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab

References

• Peyrin-Biroulet L , Fiorino G , Buisson A , Danese S . First-line therapy in adult Crohn's disease: Who should receive anti-TNF agents?. Nat Rev Gastroenterol Hepatol. 2013; 10: 345–51.
   PubMed Web of Science ®Google Scholar
• van der Valk ME , Mangen MJ , Leenders M , Dijkstra G , van Bodegraven AA , Fidder HH et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: Results from the COIN study. Gut. 2014; 63: 72–9.
   PubMed Web of Science ®Google Scholar
• Billioud V , Sandborn WJ , Peyrin-Biroulet L . Loss of response and need for adalimumab dose intensification in Crohn's disease: A systematic review. Am J Gastroenterol. 2011; 106: 674–84.
   PubMed Web of Science ®Google Scholar
• Gisbert JP , Panés J . Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am J Gastroenterol. 2009; 104: 760–7.
   PubMed Web of Science ®Google Scholar
• Nanda KS , Cheifetz AS , Moss AC . Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-analysis. Am J Gastroenterol. 2013; 108: 40–7.
   PubMed Web of Science ®Google Scholar
• O'Meara S , Nanda KS , Moss AC . Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 2014; 20: 1–6.
   PubMed Web of Science ®Google Scholar
• Paul S , Moreau AC , Del Tedesco E , Rinaudo M , Phelip JM , Genin C et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases: A systematic review and meta-analysis. Inflamm Bowel Dis. 2014; 20: 1288–95.
   PubMed Web of Science ®Google Scholar
• Sobolev B , Harel D , Vasilakis C , Levy A . Using the Statecharts paradigm for simulation of patient flow in surgical care. Health Care Manag Sci. 2008; 11: 79–86.
   Web of Science ®Google Scholar
• Le Lay A , Despiegel N , François C , Duru G . Can discrete event simulation be of use in modelling major depression?. Cost Eff Resour Alloc. 2006; 4: 19.
   Google Scholar
• Hanauer SB , Feagan BG , Lichtenstein GR , Mayer LF , Schreiber S , Colombel JF et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002; 359: 1541–9.
   PubMed Web of Science ®Google Scholar
• Cummings JR , Keshav S , Travis SP . Medical management of Crohn's disease. BMJ. 2008; 336: 1062–6.
   PubMed Web of Science ®Google Scholar
• Katz L , Gisbert JP , Manoogian B , Lin K , Steenholdt C , Mantzaris GJ et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012; 18: 2026–33.
   PubMed Web of Science ®Google Scholar
• Chaparro M , Martínez-Montiel P , Van Domselaar M , Bermejo F , Pérez-Calle JL , Casis B et al. Intensification of infliximab therapy in Crohn's disease: Efficacy and safety. J Crohns Colitis. 2012; 6: 62–7.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N , Gils A , Singh S , Ohrmund L , Hauenstein S , Rutgeerts P et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013; 108: 962–71.
   PubMed Web of Science ®Google Scholar
• Leclerc MP , Paul S , Roblin X . Cinétiques des ATI prédit la perte de réponse clinique au cours des MICI. 2014; Paris: JFHOD. 479.
   Google Scholar
• Colombel JF , Sandborn WJ , Rutgeerts P , Enns R , Hanauer SB , Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology. 2007; 132: 52–65.
   PubMed Web of Science ®Google Scholar
• Baert F , Glorieus E , Reenaers C , D'Haens G , Peeters H , Franchimont D et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis. 2013; 7: 154–60.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Hanauer S , Rutgeerts P , Fedorak RN , Lukas M , MacIntosh DG et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut. 2007; 56: 1232–9.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Rutgeerts P , Enns R , Hanauer SB , Colombel JF , Panaccione R et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: A randomized trial. Ann Intern Med. 2007; 146: 829–38.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Colombel JF , Schreiber S , Plevy SE , Pollack PF , Robinson AM et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011; 17: 141–51.
   PubMed Web of Science ®Google Scholar
• Roblin X , Rinaudo M , Del Tedesco E , Phelip JM , Genin C , Peyrin-Biroulet L et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014; 109: 1250–6.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S , Waterman M , Kopylov U , Yavzori M , Picard O , Fudim E et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013; 11: 444–7.
   PubMed Web of Science ®Google Scholar
• Paul S , Del Tedesco E , Marotte H , Rinaudo-Gaujous M , Moreau A , Phelip JM et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: A prospective study. Inflamm Bowel Dis. 2013; 19: 2568–76.
   PubMed Web of Science ®Google Scholar
• Sands BE , Feagan B , Rutgeerts P , Colombel JF , Sandborn WJ , Sy R et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147: 618–27.
   PubMed Web of Science ®Google Scholar
• Yanai H , Lichtenstein L , Assa A , Mazor Y , Weiss B , Levine A et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015; 13: 522–30.
   PubMed Web of Science ®Google Scholar
• Afif W , Loftus EV Jr. , Faubion WA , Kane SV , Bruining DH , Hanson KA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133–9.
   PubMed Web of Science ®Google Scholar
• Regueiro M , Schraut W , Baidoo L , Kip KE , Sepulveda AR , Pesci M et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441–50.
   PubMed Web of Science ®Google Scholar
• Velayos FS , Kahn JG , Sandborn WJ , Feagan BG . A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013; 11: 654–66.
   PubMed Web of Science ®Google Scholar
• Steenholdt C , Brynskov J , Thomsen OØ , Munck LK , Fallingborg J , Christensen LA et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut. 2014; 63: 919–27.
   PubMed Web of Science ®Google Scholar
• Steenholdt C , Bendtzen K , Brynskov J , Thomsen OØ , Ainsworth MA . Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: Post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014; 109(7): 1055–64.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL , Nair SC , Nurmohamed MT , van Dongen CJ , Lems WF , Lafeber FP et al. Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: An evaluation of costs and effects. Ann Rheum Dis. 2015; 74: 361–8.
   PubMed Web of Science ®Google Scholar